News headlines about Tandem Diabetes Care (NASDAQ:TNDM) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a news impact score of 0.13 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 46.4763152449703 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Tandem Diabetes Care (NASDAQ TNDM) traded down $0.05 during mid-day trading on Tuesday, hitting $2.54. The company had a trading volume of 117,700 shares, compared to its average volume of 200,783. The company has a quick ratio of 0.88, a current ratio of 1.90 and a debt-to-equity ratio of -2.70. Tandem Diabetes Care has a twelve month low of $2.15 and a twelve month high of $30.00.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, October 26th. The medical device company reported ($3.09) earnings per share for the quarter, topping the consensus estimate of ($3.74) by $0.65. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. The business had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.92 million. During the same period in the prior year, the company earned ($0.97) EPS. Tandem Diabetes Care’s revenue for the quarter was up 119.7% on a year-over-year basis. research analysts expect that Tandem Diabetes Care will post -15.37 earnings per share for the current fiscal year.
TNDM has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Wednesday, November 1st. Wedbush restated an “outperform” rating and set a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th. Piper Jaffray Companies restated a “hold” rating and set a $15.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Finally, Robert W. Baird restated a “hold” rating and set a $3.00 price objective on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Tandem Diabetes Care currently has an average rating of “Hold” and an average price target of $11.29.
In other news, CEO Kim D. Blickenstaff bought 285,700 shares of the company’s stock in a transaction on Friday, October 13th. The stock was purchased at an average cost of $3.50 per share, for a total transaction of $999,950.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.90% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Tandem Diabetes Care (TNDM) Earning Somewhat Favorable Press Coverage, Analysis Finds” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/05/tandem-diabetes-care-tndm-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with MarketBeat.com's FREE daily email newsletter.